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CRISPR/Cas9-generated p47phox-
deficient cell line for Chronic 
Granulomatous Disease gene 
therapy vector development
Dominik Wrona1,2,3, Ulrich Siler1,2,3,* & Janine Reichenbach1,2,3,*
Development of gene therapy vectors requires cellular models reflecting the genetic background 
of a disease thus allowing for robust preclinical vector testing. For human p47phox-deficient chronic 
granulomatous disease (CGD) vector testing we generated a cellular model using clustered regularly 
interspaced short palindromic repeats (CRISPR)/Cas9 to introduce a GT-dinucleotide deletion (ΔGT) 
mutation in p47phox encoding NCF1 gene in the human acute myeloid leukemia PLB-985 cell line. CGD 
is a group of hereditary immunodeficiencies characterized by impaired respiratory burst activity in 
phagocytes due to a defective phagocytic nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase. In Western countries autosomal-recessive p47phox-subunit deficiency represents the second 
largest CGD patient cohort with unique genetics, as the vast majority of p47phox CGD patients carries 
ΔGT deletion in exon two of the NCF1 gene. The established PLB-985 NCF1 ΔGT cell line reflects the 
most frequent form of p47phox-deficient CGD genetically and functionally. It can be differentiated to 
granulocytes efficiently, what creates an attractive alternative to currently used iPSC models for rapid 
testing of novel gene therapy approaches.
Chronic Granulomatous Disease (CGD) comprises a group of monogenetic immunodeficiencies characterized by 
impaired respiratory burst activity and microbicidal activity of phagocytes leading to recurrent life-threatening 
infections1. CGD can be cured by hematopoietic stem cell transplantation (HSCT)2. Alternatively, autologous 
retroviral gene therapy has been used in selected patients with X-linked CGD (X-CGD)3–7.
Mutations in gp91phox, p47phox, p67phox, p40phox or p22phox subunits of the phagocytic nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase may cause CGD8. In Western countries gp91phox-deficiency is the most 
frequent from (65%)9, followed by p47phox-deficiency (25%). Mutations within gp91phox are scattered through-
out the whole cytochrome b-245 beta chain (CYBB) gene. Conversely, p47phox-deficiency is almost exclusively 
caused by a single GT-dinucleotide deletion (Δ GT) in exon 2 of neutrophil cytosolic factor 1 (NCF1) gene caus-
ing frameshift and premature translation stop. The Δ GT deletion is shared with two pseudogenes, NCF1B and 
NCF1C, all located on the same chromosome sharing extraordinary homology (99.5%) (Fig. 1A,B). Presumably, 
homologous recombination causes the predominance of the Δ GT mutation in p47phox-deficient CGD patients10.
Currently, development of gene therapy vectors for p47phox-deficient CGD is hampered by the absence of 
human cell lines for rapid gene therapy vector testing. p47phox− /− mouse models exist, but cannot replace vector 
testing on human cells. Recently, we established human p47phox-deficient induced pluripotent stem cell (iPSC) 
lines harboring the Δ GT within the NCF1 gene11. Only these iPSC-based cell lines reflect the genetic background 
of the most frequent mutation in CGD. As maintenance and differentiation of iPSC lines is laborious and in many 
aspects impractical, we established a novel model for Δ GT p47phox-deficient CGD based on a human acute mye-
loid leukemia PLB-985 cell line12.
We nucleofected PLB-985 wild type (WT) cells with pPX458-NCF1 plasmid encoding Cas9, single guide 
RNA (sgRNA) targeting NCF1, and GFP. To introduce the Δ GT in NCF1 a 100-nucleotide long single stranded 
oligonucleotide (ssODN) template, carrying the Δ GT, was co-transfected (Fig. 1C).
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Nucleofected GFP expressing cells were sorted by fluorescence-activated cell sorting (FACS) and expanded 
to monoclonal cell lines. Out of 609 sorted cells 22 clones could be expanded (3.6% survival rate, Supplementary 
Table S1). These clones were analyzed by PCR co-amplification of NCF1, NCF1B and NCF1C alleles (Fwd1, Rev1 
primers, Fig. 1B), followed by BsrG1 digestion13. BsrG1 cleavage of NCF1 gene gives 135bp and 63bp products, 
while NCF1B, NCF1C, or mutated NCF1 lack the BsrG1 restriction site (Fig. 1C).
The BsrG1 analysis of one nucleofected PLB-985 clone displayed the same band pattern as of a Δ GT 
p47phox-deficient CGD patient (Fig. 1D and Supplementary Fig. S1), suggesting a Cas9-mediated disruption of 
the BsrG1 site in both NCF1 alleles (homozygous mutation efficiency 4.5%). The BsrG1 digestion analysis of the 
remaining clones suggested heterozygosity in these clones (Supplementary Fig. S1).
To confirm the presence of the Δ GT in mutated NCF1, genomic DNA of WT and pPX458-NCF1-treated 
PLB-985 cells were used for PCR co-amplification of the NCF1, NCF1B, and NCF1C (Fwd1, Rev2 primers, 
Fig. 1B). The barcoded PCR products were analyzed by single molecule real-time sequencing (SMRT-seq) for the 
presence of GT-dinucleotide, Δ GT, as well as for the presence of one copy of 20-nucleotide (20-nt) intronic repeat 
(1 × 20nt) derived from NCF1 or two repeats (2 × 20nt) derived from NCF1B or NCF1C (Fig. 1B). SMRT-seq 
analysis showed that PLB-985 WT and PLB-985 NCF1 Δ GT cell lines displayed almost identical percentage 
(61%) of reads with one or two copies of the 20-nucleotide repeat (Fig. 1E), indicating that all three NCF1 loci 
were co-amplified with comparable efficiencies. Moreover, all SMRT-seq reads from PLB-985 NCF1 Δ GT dis-
played the Δ GT, while in PLB-985 WT 37.4% harbored the GT-dinucleotide sequence, as expected from the two 
NCF1 alleles.
Potential off-target sites of utilized sgRNA were predicted (Supplementary Table S2) and DNA sequences of 14 
sites with highest scores were analyzed for presence of insertions or deletions (indels) by Surveyor assay. In none 
of the potential off-target sites indels were observed (Supplemetary Fig. S2).
Flow cytometry analysis of granulocytically differentiated PLB-985 WT and PLB-985 X-CGD cells14 revealed 
86.1% and 89.4% of p47phox protein expressing cells (Fig. 2A) (gating, Supplementary Fig. S3). No p47phox expres-
sion was observed in differentiated PLB-985 NCF1 Δ GT cells, which were CD14-negative, CD15-positive and 
partially gp91phox-positive (Supplementary Fig. S4).
To confirm that differentiated PLB-985 NCF1 Δ GT cells mirror the absent respiratory burst observed in pri-
mary neutrophils of Δ GT p47phox-deficient CGD patients, we tested this cell line for NADPH oxidase-mediated 
superoxide production with nitroblue tetrazolium (NBT) test. In differentiated PLB-985 WT cells, phorbol-
12-myristate-13-acetate (PMA)-stimulation induced superoxide production in 47.8 ± 4.2% of cells, as was visual-
ized by formazan precipitates (Fig. 2B and Supplementary Fig. S5). In contrast, PMA-stimulation of differentiated 
Figure 1. NCF1 loci in PLB-985 cell lines. (A) NCF1 gene is flanked by two pseudogenes, NCF1B and NCF1C. 
(B) Differentiators between NCF1 and pseudogenes. PCR primers: Fwd1, Rev1, Rev2. (C) DNA sequence of 
GT-dinucleotide and 20 nucleotide repeat loci. CRISPR/Cas9-targeted sequence, protospacer adjacent motif 
(PAM) and BsrG1 site: rectangles; 20-nucleotide repeat: squared brackets. (D) Loss of BsrG1 restriction site in 
PCR amplified NCF1 (B,C) exon 2 (primers Fwd1 and Rev1 (B)) in PLB-985 NCF1 Δ GT cells. Full-length gel is 
presented in Supplementary Fig. S6. (E) Percentages of reads from SMRT-seq of PCR products (primers Fwd1 
and Rev2 (B)). The absolute number of analyzed SMRT sequencing reads which have passed all filtering criteria 
is given.
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PLB-985 X-CGD and PLB-985 NCF1 Δ GT cells resulted only in background signal of 1.7 ± 1.0% and 0.9 ± 0.5%. 
These results indicate that the established p47phox-deficient PLB-985 NCF1 Δ GT cell line does not respond to 
PMA-stimulation by reactive oxygen species (ROS) production. The absence of ROS production in PLB-985 
X-CGD and PLB-985 NCF1 Δ GT cells was confirmed by chemiluminescence assay (Fig. 2C).
The iPSC model of Δ GT p47phox-deficient CGD11 can be differentiated to monocytes, macrophages11 
and granulocytes15,16. Nevertheless, the use of iPSCs is laborious, and time-consuming, as phagocytic dif-
ferentiation requires long culture periods of 35–43 days15,17 requiring large amounts of cytokines and 
continuous surveillance of the culture. In contrast full granulocytic differentiation of PLB-985 NCF1  
Δ GT cell line takes 7 days, requires only fetal calf serum (FCS) restriction (5%) and supplementation with 0.5% 
N,N-dimethylformamide (DMF). Furthermore, the differentiation of neutrophils can be easily assessed by flow 
cytometry (Supplementary Fig. S3).
The function of the NADPH oxidase complex within PLB-985 NCF1 Δ GT cells was reconstituted by trans-
duction with two γ -retroviral vectors encoding p47phox protein (Fig. 2D). Transgene expression was driven either 
by the ubiquitously active spleen focus-forming virus (SFFV) promoter or by the myelospecific microRNA 223 
(mir223) promoter18. The expression cassette was composed of truncated Low-affinity nerve growth factor recep-
tor (Δ LNGFR) and p47phox linked by the 2 A self-cleaving peptide19. Transduction efficiency reached 8.9% and 
11.6% for mir223, and SFFV-driven γ -retroviral vectors (Fig. 2E).
Figure 2. Superoxide production in PLB-985 NCF1 ΔGT. (A) p47phox flow cytometry analysis and 
(B) ROS production in granulocytically differentiated PLB-985, PLB-985 X-CGD and PLB-985 NCF1 Δ GT 
cells measured by NBT test. NBT-positive: black arrow; NBT-negative: white arrows. Scale bar: 25 μ m. 
(C) Chemiluminescence assay of un-transduced PLB-985 WT, PLB-985 NCF1 Δ GT, and PLB-985 X-CGD 
cell line (mean and standard deviation of mean, n = 3, a.u. = arbitrary units). (D) γ -retroviral vectors for 
reconstitution of p47phox expression. (E) Flow cytometry analysis of p47phox and Δ LNGFR expression in 
differentiated un-transduced PLB-985 WT and PLB-985 NCF1 Δ GT, and transduced PLB-985 NCF1 Δ GT 
cells. (F) ROS production in transduced PLB-985 NCF1 Δ GT cells upon differentiation, measured by NBT test. 
NBT-positive: black arrow; NBT-negative: white arrows. Scale bar: 25 μ m. (G) Chemiluminescence assay of 
transduced PLB-985 NCF1  Δ GT cells (mean and standard deviation of mean, n = 3).
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Functional reconstruction of the NADPH oxidase complex activity in transduced and differentiated PLB-
985 NCF1 Δ GT cells was assessed by NBT assay (Fig. 2F) and chemiluminescence assay (Fig. 2G). Percentage 
of NBT-positive cells reached 13.4 ± 2.1% with the mir223, and 11.8 ± 1.8% with the SFFV-driven Δ LNGFR-
2A-p47phox expression constructs (Fig. 2F and Supplementary Fig. S5). Chemiluminescence assay of transduced and 
differentiated PLB-985 NCF1 Δ GT cells confirmed reconstitution of ROS production. These results clearly indicate 
that the defect of the NADPH oxidase complex caused by the Δ GT mutation within NCF1 in the PLB-985 NCF1 
Δ GT cell line can be corrected.
In summary, the CRISPR/Cas9-generated PLB-985 NCF1 Δ GT cell line fully recapitulates the genetic back-
ground and functional NADPH oxidase defect found in majority of p47phox-deficient CGD patients, can be cor-
rected genetically and differentiated into functional neutrophils. The PLB-985 NCF1 Δ GT cell line therefore 
represents a promising cost-effective tool for rapid gene therapy vector testing.
Materials and Methods
Reagents and antibodies. Single stranded DNA was purchased from Microsynth (Balgach, Switzerland). 
RPMI 1640 medium with stable glutamine and fetal calf serum (FCS) were purchased from PAN-Biotech 
(Aidenbach, Germany). Penicillin/streptomycin, Phusion High-Fidelity DNA Polymerase, and dNTPs were 
obtained from Thermo Fisher (Reinach, Switzerland), SCR7 was from Biovision (Milpitas, CA). BsrG1 was 
derived from New England Biolabs (Frankfurt/Main, Germany). N,N-dimethylformamide (DMF), propidium 
iodide (PI) and nitro blue tetrazolium (NBT) were obtained from Sigma Aldrich (Buchs, Switzerland). Mouse 
anti-human Δ LNGFR monoclonal antibody, clone ME20.4–1.H4, fluorescein isothiocyanate (FITC)-conjugated 
was purchased from Miltenyi Biotec (Bergisch Gladbach, Germany), and mouse anti-human p47phox monoclo-
nal antibody clone 1 was allophycocyanin (APC)-conjugated by Becton Dickinson AG (Allschwil, Switzerland). 
PECy7-conjugated anti-mouse/human CD11b antibody was from BioLegend (Fell, Germany). Mouse anti-hu-
man CD15 FITC (Catalog no 347423) and mouse anti-human CD14 FITC (Catalog no. 345784) were from 
Beckton Dickinson AG (Allschwil, Switzerland). Mouse anti-Flavocytochrome b558 (human)-FITC clone 7D5 
recognizing gp91phox was from LabForce AG (Muttenz, Switzerland).
Plasmid preparation. The sgRNA sequence targeting the NCF1 gene (but not NCF1B and NCF1C pseu-
dogenes) was designed using Optimized CRISPR Design (http://crispr.mit.edu, F. Zhang laboratory, MIT 2015). 
Guide sequence CCCCCAGGTGTACATGTTCC was cloned into pSpCas9(BB)-2A-GFP (PX458) (F. Zhang, 
Addgene plasmid #48138)20 to generate pPX458-NCF1, which was confirmed by sequencing (Microsynth).
Cell culture and differentiation. We utilized PLB-985 cell line12, a subclone of HL-6021,22, as it is capable 
of granulocytic differentiation. Cells were cultured in RPMI 1640 medium supplemented with 10% (vol/vol) FCS, 
and 1% (vol/vol) penicillin/streptomycin in a humidified incubator at 37 °C and 5% CO2. Granulocytic differen-
tiation of logarithmically growing PLB-985 cells at density of 0.8·106 cells/mL was induced by reduction of the 
FCS content to 5%, and supplementation with 0.5% (vol/vol) DMF. After 3 days, an equivalent of initial volume 
of differentiating medium was added and the differentiation continued until day 7.
CRISPR/Cas9 mediated generation of PLB-985 NCF1 ΔGT cell line. 2·106 PLB-985 wild type (WT) 
cells were nucleofected (Amaxa Cell Nucleofector Kit V and Amaxa Nucleofector II, program C-023 (Lonza, 
Basel, Switzerland)) with 40 μ g of the pPX458-NCF1 and a 100-nucleotide long ssODN sequence at final concen-
tration 3 μ M. The sequence of the ssODN was: GCC TCT TTG GAG GCT GAA TGG GGT CCC CCG ACT CTG 
GCT TTC CCC CAG GTA CAT GTT CCT GGT GAA ATG GCA GGA CCT GTC GGA GAA GGT GGT CTA 
CCG G. Immediately after nucleofection 500 μ L of medium was added to the cuvette and the cells were incubated 
at room temperature for 10 minutes, transferred to 10 mL medium, then cultured for 48 hours. Additionally, the 
culture was supplemented with 1 μ M SCR7 starting 3–4 hours post nucleofection. After 48 hours GFP expressing 
cells were sorted with FACS Aria III FCF (Becton Dickinson AG, Allschwil, Switzerland) into single wells with 
100 μ L of pre-conditioned, sterile filtered medium supplemented with 1 μ M SCR7.
DNA Amplification and Restriction Fragment Length Polymorphism Analysis. Processing of 
human samples is covered by ethical vote KEK ZH nr. 2015/0135. Genomic DNA was isolated using DNeasy 
Blood & Tissue Kit (Qiagen, Hombrechtikon, Switzerland). Parallel PCR co-amplification of the NCF1, NCF1B, 
and NCF1C was performed using published primers23 (Fwd1 and Rev1, Fig. 1B). For PCR reaction using Fwd1/
Rev2 primers Fwd1 primer was barcoded for each template producing products of 417 bp from NCF1 and of 
435 bp from NCF1B and NCF1C. PCR products were pooled for SMRT sequencing and analyzed according to 
barcode identities.
The PCR mixture included HF 10× buffer, 200 μ M of each dNTP, 240 nM of each primer, 0.04 U/μ L of Phusion 
High-Fidelity DNA Polymerase, and 2.5 ng/μ L of genomic DNA. Initial denaturation at 95 °C for 3 minutes was 
followed by 36 cycles of denaturation (95 °C, 30 seconds), annealing (70 °C, 30 seconds), elongation (72 °C, 8 sec-
onds), and a final elongation step (72 °C, 1 minute). PCR products were digested with BsrG1 and visualized on a 
3% (w/vol) agarose gel.
Single molecule real-time (SMRT) sequencing. The NCF1 gene and NCF1B and NCF1C pseudogenes 
were PCR amplified in parallel utilizing primers Fwd1 and Rev2 (Fig. 1B)23. The primer Fwd1 was barcoded 
for each FACS sorted clone and obtained PCR products were of 417 bp for NCF1 and 435 bp for NCF1B and 
NCF1C templates. PCR reaction consisted of initial denaturation (95 °C, 3 minutes), 40 cycles of denaturation 
(95 °C, 30 seconds), annealing (60 °C, 30 seconds), elongation (72 °C, 30 seconds), and a final elongation step 
(72 °C, 3 minutes). PCR products were gel purified using QIAquick Gel Purification Kit (Qiagen). 10–20 ng of 
gel-purified PCR products were pooled and analyzed by SMRT sequencing by Functional Genomics Center 
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Zurich, ETH/University of Zurich, Zurich, Switzerland. Briefly, DNA amplicon librabry was produced using 
DNA Template Prep Kit 1.0 (Pacific Biosciences, Menlo Park, California, United States). The input DNA con-
centration and quality was measuered using Qubit Fluorometer dsDNA Broad Range assay (Life Technologies, 
Zug, Switzerland) and Bioanalyzer 2100 12 K DNA Chip assay (Agilent Technologies AG, Basel, Switzerland). 
The SMRT bell template was prepared by end-repair of the DNA amplicons, followed by blunt-end ligation of 
overhang adapters and exonuclease treatment. The SMRT bell template was complexed with polymerase using P6 
DNA/Polymerase Binding Kit 2.0 (Pacific Biosciences) according to the manufacturer’s instructions. The samples 
were sequenced using Pacific Biosciences RS2 platform. From the raw reads, high quality circular consensus 
reads (CCS) were obtained through the Reads Of Insert protocol available in the SMRT Analysis suite (Pacific 
Biosystems). CCS reads were then de-multiplexed by exact matching of the sample barcodes, starting at the base 
immediately preceeding the Fwd1 primer sequence. Reads with a length between 400 and 450 nucleotides were 
retained and matched against the NCF1 reference sequence using blast24.
Surveyor Assay. Off-target sites were predicted utilizing the Optimized CRISPR Design (http://crispr.mit.
edu, F. Zhang laboratory, MIT 2015). Loci of predicted sites (see Supplementary Table S2) were PCR amplified 
from gDNA of PLB-985 WT and PLB-985 NCF1 Δ GT cells. Corresponding PCR amplification products were 
mixed in a ratio of 1:1, while PCR amplification product of PLB-985 WT was used as a control. The samples were 
denatured at 95 °C for 10 minutes, slowly renatured, and digested using Surveyor® Mutation Detection Kit For 
Standard Gel Electrophoresis (Integrated DNA Technologies, Leuven, Belgium) according to the manufacturer’s 
instructions.
Data Availability. All SMRT sequencing data can be obtained upon request.
Virus production and transduction. Viruses were produced as described previously19. In brief, 
293T cells were co-transfected with pUMVC, pMD2.VSV.G and γ SIN-SFFV-Δ LNGFR-2A-p47phox 19 or 
γ SIN-miR223-Δ LNGFR-2A-p47phox 18 in presence of 10 mM chloroquine. Sterile filtered virus containing super-
natants were concentrated using Amicon-15 centrifugal filter devices with 100 kDa cutoff and stored at − 80 °C 
until use.
PLB-985 NCF1 Δ GT cells were γ -retrovirally transduced with vectors co-encoding p47phox protein and 
low-affinity nerve growth factor receptor (Δ LNGFR)18,19 at concentration of 0.8·106 cells/mL, at multiplicity of 
infection (MOI) = 5, and in presence of 8 μ g/mL protamine sulfate by spinoculation at 1286 g, 32 °C for 90 min-
utes, followed by incubation at 37 °C and 5% CO2 for 24 hours. Then, cells were differentiated into granulocytes in 
presence of 0.5% DMF and 5% FCS for 6 days and analyzed thereafter.
Flow cytometry analysis. Δ LNGFR surface staining was carried out with 6 μ L of mouse anti-LNGFR-FITC 
(Miltenyi Biotec) per 5 * 105 cells in 100 μ L for 20 minutes, followed by washing in PBS. Intracellular staining of 
p47phox was conducted utilizing 360 ng of mouse anti-p47phox-APC (clone 1) per 5 * 105 cells in 100 μ L and the 
IntraCell Kit (Immunostep, Salamanca, Spain) according to the manufacturer’s instructions. Flow cytometry 
analysis was performed using a Gallios Flow Cytometer (Beckman Coulter).
Nitroblue-tetrazolium (NBT) test. Differentiated PLB-985 WT, PLB-985 X-CGD, and PLB-985 NCF1 
Δ GT cells, as well as transduced PLB-985 NCF1 Δ GT cells were incubated in growth medium supplemented 
with 100 μ g/mL NBT in the presence of 200 ng/mL PMA at 37 °C and 5% CO2 for 30 minutes. Subsequently, the 
cells were fixed in 1% (vol/vol) formaldehyde. 250 cells per cytospin slide were analyzed manually for NBT activ-
ity using a Leica DM IL Fluo light microscope equipped with a DFC420 digital camera and LEICA application 
suite acquisition software (Leica Microsystems AG, Glattbrugg, Switzerland).
Chemiluminescence assay. Chemiluminescence assay on differentiated PLB-985 WT, PLB-985 X-CGD, 
and PLB-985 NCF1 Δ GT cells, as well as transduced PLB-985 NCF1 Δ GT was conducted in 96-well plate format 
at a cell density of 1 * 105 cells/200 ml in a Mithras LB 940 Luminometer (Berthold Technologies GmbH, Zug, 
Switzerland) as described recently11.
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